Overall, our findings suggest that YIV-818-A, RA-V, and RA-VII hold promise as potential treatments for prostate cancers with AR, AR-V (AR splice variants) and might be beneficial in enzalutamide-resistant cases with GR overexpression. The gene discussed is NR3C1; the disease is prostate carcinoma.